Document:

<PAGE>   1
                                                                     Exhibit 4.2

                        [BIOMUNE CORPORATION LETTERHEAD]

                                  June 14, 2001

Mr. Thomas L. Amberg
180 North Michigan Avenue
Chicago, IL 60601

Dear Tom:

    This letter sets forth the terms whereby Biomune Systems, Inc., a Nevada
corporation ("Biomune"), agrees to retain Michael Acton to act as consultant and
advisor to Biomune in the are of media relations. In exchange for your services,
Biomune shall deliver to you 10,000 shares of Common Stock of Biomune, par value
$0.0001 per share, (the "Shares"), which will be duly authorized, legally and
validly issued and outstanding, fully paid, non-assessable and registered
pursuant to the Securities Act of 1933, as amended. The Shares will be issued to
you upon an effective registration statement.

    In exchange for the Shares, you shall provide to Biomune direction with
respect to media and public relations, along with any other activities or
services requested by Biomune relating to typical public relations activities.

    If the foregoing is in accordance with your understanding of our agreement,
please sign where indicated below and deliver a copy of this letter as provided
for herein, whereupon this letter shall represent a binding agreement between
us.

                                                  Very truly yours,

                                                  BIOMUNE SYSTEMS, INC.

                                                  By:
                                                     ---------------------------
                                                     Name: Larry Koskan
                                                     Title: President and CEO

Accepted and agreed to
as of the date first
above written:

---------------------------------
Thomas L. Amberg<PAGE>   1
                                                                     Exhibit 4.3

                        [BIOMUNE CORPORATION LETTERHEAD]

                                  June 14, 2001

Dr. A.P. Wheeler
Dept of Biological Sciences
132 Long Hall
Clemson, SC 29634-1903

Dear Hap:

    This letter sets forth the terms whereby Biomune Systems, Inc., a Nevada
corporation ("Biomune"), agrees to retain Dr. A.P. Wheeler to act as consultant
and advisor to Biomune regarding biodegradable research. In exchange for your
services, Biomune shall deliver to you 10,000 shares of Common Stock of Biomune,
par value $0.0001 per share, (the "Shares"), which will be duly authorized,
legally and validly issued and outstanding, fully paid, non-assessable and
registered pursuant to the Securities Act of 1933, as amended. The Shares will
be issued to you upon an effective registration statement.

    In exchange for the Shares, you shall provide to Biomune direction on a wide
variety of biodegradable research programs, along with any other activities or
services requested by Biomune relating to research activities.

    If the foregoing is in accordance with your understanding of our agreement,
please sign where indicated below and deliver a copy of this letter as provided
for herein, whereupon this letter shall represent a binding agreement between
us.

                                                  Very truly yours,

                                                  BIOMUNE SYSTEMS, INC.

                                                  By:
                                                     ---------------------------
                                                     Name: Larry Koskan
                                                     Title: President and CEO

Accepted and agreed to
as of the date first
above written:

---------------------------------
Dr. A.P. Wheeler<PAGE>   1
                                                                     Exhibit 4.4

                        [BIOMUNE CORPORATION LETTERHEAD]

                                  June 13, 2001

Mr. Ramon Georgis
250 E. Church
Elmhurst, IL 60126

Dear Ramon:

    This letter sets forth the terms whereby Biomune Systems, Inc., a Nevada
corporation ("Biomune"), agrees to retain Ramon Georgis to act as consultant and
advisor to Biomune in the capacity as an agricultural research advisor for crop
nutrition management. In exchange for your services, Biomune shall deliver to
you 6,000 shares of Common Stock of Biomune, par value $0.0001 per share, (the
"Shares"), which will be duly authorized, legally and validly issued and
outstanding, fully paid, non-assessable and registered pursuant to the
Securities Act of 1933, as amended. The Shares will be issued to you upon an
effective registration statement and adjusted to maintain value.

    In exchange for the Shares, you shall provide to Biomune agricultural
analysis on a wide variety of field trials, along with any other activities or
services requested by Biomune relating to the field of agriculture.

    If the foregoing is in accordance with your understanding of our agreement,
please sign where indicated below and deliver a copy of this letter as provided
for herein, whereupon this letter shall represent a binding agreement between
us.

                                                  Very truly yours,

                                                  BIOMUNE SYSTEMS, INC.

                                                  By:
                                                     ---------------------------
                                                     Name: Larry Koskan
                                                     Title: President and CEO

Accepted and agreed to
as of the date first
above written:

---------------------------------
Ramon Georgis<PAGE>   1
                                                                     Exhibit 4.5

                        [BIOMUNE CORPORATION LETTERHEAD]

                                  June 14, 2001

Mr. Allan Sweig
1553 Knollwood Lane
Highland Park, IL 60035

Dear Allan:

    This letter sets forth the terms whereby Biomune Systems, Inc., a Nevada
corporation ("Biomune"), agrees to retain Allan Sweig to act as consultant and
advisor to Biomune in the area of financing. In exchange for your services,
Biomune shall deliver to you 3,500 shares of Common Stock of Biomune, par value
$0.0001 per share, (the "Shares"), which will be duly authorized, legally and
validly issued and outstanding, fully paid, non-assessable and registered
pursuant to the Securities Act of 1933, as amended. The Shares will be issued to
you upon an effective registration statement and adjusted to maintain value.

    In exchange for the Shares, you shall provide to Biomune advice and
direction with respect to a variety of financing activities, along with any
other activities or services requested by Biomune relating to financing
activities.

    If the foregoing is in accordance with your understanding of our agreement,
please sign where indicated below and deliver a copy of this letter as provided
for herein, whereupon this letter shall represent a binding agreement between
us.

                                                  Very truly yours,

                                                  BIOMUNE SYSTEMS, INC.

                                                  By:
                                                     ---------------------------
                                                     Name: Larry Koskan
                                                     Title: President and CEO

Accepted and agreed to
as of the date first
above written:

---------------------------------
Allan Sweig<PAGE>   1
                                                                     Exhibit 4.6

                        [BIOMUNE CORPORATION LETTERHEAD]

                                  June 14, 2001

Mr. Jacob J. Guth
1245 Friendship Lane
Upper Black Eddy, PA 18972

Dear Jacob:

    This letter sets forth the terms whereby Biomune Systems, Inc., a Nevada
corporation ("Biomune"), agrees to retain Jacob J. Guth to act as consultant and
advisor to Biomune in the area of adhesives and seed coatings. In exchange for
your services, Biomune shall deliver to you 21,800 shares of Common Stock of
Biomune, par value $0.0001 per share, (the "Shares"), which will be duly
authorized, legally and validly issued and outstanding, fully paid,
non-assessable and registered pursuant to the Securities Act of 1933, as
amended. The Shares will be issued to you upon an effective registration
statement and will be adjusted to reflect the agreed to value.

    In exchange for the Shares, you shall provide to Biomune advice and
direction with respect to a variety of research, along with any other activities
or services requested by Biomune relating to adhesives and feed coating
activities.

    If the foregoing is in accordance with your understanding of our agreement,
please sign where indicated below and deliver a copy of this letter as provided
for herein, whereupon this letter shall represent a binding agreement between
us.

                                                  Very truly yours,

                                                  BIOMUNE SYSTEMS, INC.

                                                  By:
                                                     ---------------------------
                                                     Name: Larry Koskan
                                                     Title: President and CEO

Accepted and agreed to
as of the date first
above written:

---------------------------------
Jacob J. Guth<PAGE>   1

                                                                   EXHIBIT 10.46
                             1998 STOCK OPTION PLAN
                              FOR KEY EMPLOYEES OF
                     MEDCATH HOLDINGS, INC. AND SUBSIDIARIES

1.       Purpose of Plan

         The 1998 Stock Option Plan for Key Employees of MedCath Holdings, Inc.
and Subsidiaries (the "Plan") is designed:

         (a) to promote the long term financial interests and growth of MedCath
Holdings, Inc. (the "Company") and its subsidiaries by attracting and retaining
management personnel with the training, experience and ability to enable them to
make a substantial contribution to the success of the Company's business;

         (b) to motivate management personnel by means of growth-related
incentives to achieve long range goals; and

         (c) to further the alignment of interests of participants with those of
the stockholders of the Company through opportunities for increased stock, or
stock-based, ownership in the Company.

2.       Definitions

         As used in the Plan, the following words shall have the following
meanings:

         (a) "Board of Directors" means the Board of Directors of the Company.

         (b) "Code" means the Internal Revenue Code of 1986, as amended.

         (c) "Committee" means the Compensation Committee of the Board of
Directors.

         (d) "Common Stock" or "Share" means Common Stock of the Company which
may be authorized but unissued, or issued and reacquired.

         (e) "Employee" means a person, including an officer, in the regular
full-time employment of the Company or of its Subsidiaries who, in the opinion
of the Committee is, or is expected to be, responsible for the management,
growth or protection of some part or all of the business of the Company.
Notwithstanding the foregoing, "Employee" may also mean a person including an
officer, employed by the Company on a less than full-time basis, if approved by
the Committee.

         (f) "Employee Stockholder's Agreement" means an agreement dated as of
July 31, 1998 between the Company and a Participant that sets forth the terms
and conditions and limitations applicable to any Shares purchased pursuant to
Options granted under this Plan.

<PAGE>   2

         (g) "Exchange Act" means the Securities Exchange Act of 1934, as
amended.

         (h) "Fair Market Value" of a Share means:

                  (i) As of any date the Shares are not listed on a national
         securities exchange or traded on the Nasdaq National Market and during
         the 180 day period following the effectiveness of an underwritten
         public offering of the Shares, the quotient of Amount A divided by
         Amount B, where:

                  Amount A is the amount determined by the following formula:

                  (Consolidated EBITDA for the immediately preceding fiscal year
                  of the Company times 9) minus Consolidated Debt as of the last
                  day of the immediately preceding fiscal year of the Company
                  plus Consolidated Unrestricted Cash as of the last day of the
                  immediately preceding fiscal year of the Company plus
                  (Unconsolidated Affiliate Interest for the immediately
                  preceding fiscal year of the Company times 8); and

                  Amount B is the number of fully diluted Shares outstanding as
                  of such date (including the number of Shares that would be
                  issued if (i) all vested and exercisable Options designated as
                  Time Options in the applicable Option Agreement and (ii) all
                  vested and exercisable options under the MedCath Holdings,
                  Inc. Outside Directors' Stock Option Plan as of said date were
                  exercised).

                  (ii) As of any other date, the closing sale price at which the
         Shares are sold regular way on a national securities exchange or the
         Nasdaq National Market on said date, or, if no sales occur on such
         date, then on the next preceding date on which there were such sales of
         the Shares.

         (i) "Management Stockholders' Agreement" means an agreement dated as of
July 31, 1998 between the Company and a Participant that sets forth the terms
and conditions and limitations applicable to any Shares purchased pursuant to
Options granted under this Plan.

         (j) "Option Agreement" means an agreement between the Company and a
Participant that sets forth the terms, conditions and limitations applicable to
a grant of Options pursuant to the Plan.

         (k) "Option" means an option to purchase shares of the Common Stock.
Options can be either incentive stock options under Section 422 of the Code or
non-qualified stock options.

         (l) "Participant" means an Employee, or other person having a
relationship with the Company or one of its Subsidiaries, to whom one or more
grants of Options have been made and such grants have not all been forfeited or
terminated under the Plan.

         (m) "Stockholder's Agreements" shall mean the Employee Stockholder's
Agreement and the Management Stockholder's Agreement, collectively.

                                       2
<PAGE>   3

         (n) "Subsidiary" means any corporation, partnership, limited liability
company, association, joint venture or other entity whose accounts are
consolidated with the accounts of the Company in the Company's consolidated
financial statements.

         (o) "Consolidated Unrestricted Cash" as of any date means the sum of
(i) the unrestricted cash and cash equivalents reportable on a consolidated
balance sheet of the Company and the Subsidiaries prepared as of such date in
accordance with GAAP and the Company's accounting policies plus (ii) the
aggregate exercise price for (A) all vested and exercisable Options designated
as Time Options in the applicable Option Agreement and (B) all vested and
exercisable options under the MedCath Holdings, Inc. Outside Directors' Stock
Option Plan as of said date.

         (p) "Consolidated Debt" as of any date means the long and short-term
debt reportable on a consolidated balance sheet of the Company and the
Subsidiaries prepared as of such date in accordance with GAAP and the Company's
accounting policies.

         (q) "Consolidated EBITDA" for a period means the sum of (i)
Consolidated Net Income for such period less the minority interest share of such
Consolidated Net Income plus (ii) the amounts which have been deducted in the
determination of Consolidated Net Income for such period for pre-hospital
opening expense, interest expense, total federal, state, local and foreign
income taxes and depreciation and amortization expense.

         (r) "Consolidated Net Income" for a period means the consolidated net
income (loss) of the Company and the Subsidiaries (excluding (i) non-recurring
transactions and items and (ii) Unconsolidated Affiliate Interest) after
interest expense, income and similar taxes and depreciation and amortization for
such period, all as determined in accordance with GAAP and the Company's
accounting policies applied on a consistent basis.

         (s) "GAAP" means generally accepted accounting principles in the United
States applied on a consistent basis.

         (t) "Unconsolidated Affiliate Interest" for a period means the
Company's interest in the net income or loss of unconsolidated affiliates for
such period as determined in accordance with the equity method of accounting
under GAAP and the Company's accounting policies applied on a consistent basis.

3.       Administration of Plan

         (a) The Plan shall be administered by the Committee; provided, however,
that the members of the Committee shall qualify to administer the Plan for
purposes of Rule 16b-3 (and any other applicable rule) promulgated under Section
16(b) of the Exchange Act to the extent that the Company is subject to such
rule. The Committee may adopt its own rules of procedure, and action of a
majority of the members of the Committee taken at a meeting, or action taken
without a meeting by unanimous written consent, shall constitute action by the
Committee. The Committee shall have the power and authority to administer,
construe and interpret the Plan, to

                                       3
<PAGE>   4

make rules for carrying it out and to make changes in such rules. Any such
interpretations, rules and administration shall be consistent with the basic
purposes of the Plan.

         (b) The Committee may delegate to the Chief Executive Officer and to
other senior officers of the Company its duties under the Plan subject to such
conditions and limitations as the Committee shall prescribe except that only the
Committee may designate and make Option grants to Participants who are subject
to Section 16 of the Exchange Act.

         (c) The Committee may employ attorneys, consultants, accountants,
appraisers, brokers or other persons. The Committee, the Company, and the
officers and directors of the Company shall be entitled to rely upon the advice,
opinions or valuations of any such persons. All actions taken and all
interpretations and determinations made by the Committee in good faith shall be
final and binding upon all Participants, the Company and all other interested
persons. No member of the Committee shall be personally liable for any action,
determination or interpretation made in good faith with respect to the Plan or
Option grants, and all members of the Committee shall be fully protected by the
Company with respect to any such action, determination or interpretation.

4.       Eligibility

         The Committee may from time to time make Option grants under the Plan
to such Employees, or other persons having a relationship with the Company or
any of its Subsidiaries, and in such form and having such terms, conditions and
limitations as the Committee may determine. No Option grants may be made under
this Plan to directors of the Company or any of its Subsidiaries who are not
also employed by the Company or one of its Subsidiaries. Options may be granted
singly, in combination or in tandem. The terms, conditions and limitations of
each Option grant under the Plan shall be set forth in an Option Agreement, in a
form approved by the Committee, consistent, however, with the terms of the Plan
and the applicable Stockholder's Agreement.

5.       Grants

         From time to time, the Committee, in its sole discretion, will
determine the forms and amounts of Options to be granted to Participants,
including whether such Options shall be incentive stock options or non-qualified
stock options. At the time of an Option grant, the Committee shall determine,
and shall include in the Option Agreement or other Plan rules, the option
exercise period, the option price, and such other conditions or restrictions on
the grant or exercise of the Option as the Committee deems appropriate. In
addition to other restrictions contained in the Plan, an Option granted under
this Paragraph 5, (i) may not be exercised more than 10 years after the date it
is granted and (ii) may not have an option exercise price less than the par
value of the Common Stock on the date the Option is granted. Payment of the
option price shall be made in cash or in shares of Common Stock, or a
combination thereof, in accordance with the terms of the Plan, the Option
Agreement and of any applicable guidelines of the Committee in effect at the
time; provided, however, that any Options granted in replacement of options held
by a Participant pursuant to any MedCath, Inc. stock option plan shall be
subject

                                       4
<PAGE>   5

to such other terms and conditions as provided for in the applicable
Stockholder's Agreement and other related documents.

         Options may be granted prior to the effective date of the Plan (as
determined pursuant to Paragraph 13 herein); provided, however, that no Option
shall be Exercisable prior to the date of the approval of the Plan by the
stockholders of the Company.

6.       Limitations and Conditions

         (a) The number of Shares available under this Plan shall be
____________ shares of the authorized Common Stock as of the effective date of
the Plan, all of which are available for grants of incentive stock options. The
number of Shares subject to Options under this Plan to any one Participant shall
not be more than ____________ Shares. The foregoing limitations shall not
include the number of Shares in respect of which Options are granted in respect
of options on shares of common stock of MedCath, Inc. that were rolled over into
the Company and this Plan pursuant to the applicable Stockholder's Agreement
between the Company and certain employees. Unless restricted by applicable law,
Shares related to Options that are forfeited, terminated, cancelled or expire
unexercised, shall immediately become available to be subject to Option grants.

         (b) No Options shall be granted under the Plan beyond ten years after
the effective date of the Plan, but the terms of Options granted on or before
the expiration of the Plan may extend beyond such expiration. At the time an
Option is granted or amended or the terms or conditions of an Option are
changed, the Committee may provide for limitations or conditions on such grant
or purchase consistent with the terms of the applicable Stockholder's Agreement.

         (c) Nothing contained herein shall affect the right of the Company to
terminate any Participant's employment at any time or for any reason, subject to
the terms and conditions of any other agreement a Participant may have with the
Company.

         (d) Other than as specifically provided with regard to the death of a
Participant or this Section 6(d), no benefit under the Plan shall be subject in
any manner to anticipation, alienation, sale, transfer, assignment, pledge,
encumbrance, or charge, and any attempt to do so shall be void. No such benefit
shall, prior to receipt thereof by the Participant, be in any manner liable for
or subject to the debts, contracts, liabilities, engagements, or torts of the
Participant; provided, however, the Participant may, for purposes of estate or
gift tax planning purposes, transfer any Options granted to the Participant to
any family member, trust, or other estate or gift tax planning vehicle, so long
as any such permitted transferee agrees to be bound by all terms and conditions
to which the transferring Participant is subject and such Participant is
designated as the exclusive authorized representative for purposes of making any
decisions with respect to such transferred Options.

         (e) Participants shall not be, and shall not have any of the rights or
privileges of, stockholders of the Company in respect of any Shares purchasable
in connection with any Option grant unless and until certificates representing
any such Shares have been issued by the Company to such Participants.

                                       5
<PAGE>   6

         (f) No election as to benefits or exercise of Options may be made
during a Participant's lifetime by anyone other than the Participant except by a
legal representative appointed for or by the Participant.

         (g) Absent express provisions to the contrary, any grant of Options
under this Plan shall not be deemed compensation for purposes of computing
benefits or contributions under any retirement plan of the Company or its
Subsidiaries and shall not affect any benefits under any other benefit plan of
any kind now or subsequently in effect under which the availability or amount of
benefits is related to level of compensation. This Plan is not a "Retirement
Plan" or "Welfare Plan" under the Employee Retirement Income Security Act of
1974, as amended.

         (h) Unless the Committee determines otherwise, no benefit or promise
under the Plan shall be secured by any specific assets of the Company or any of
its Subsidiaries, nor shall any assets of the Company or any of its Subsidiaries
be designated as attributable or allocated to the satisfaction of the Company's
obligations under the Plan.

7.       Transfers and Leaves of Absence

         For purposes of the Plan, unless the Committee determines otherwise:
(a) a transfer of a Participant's employment without an intervening period of
separation among the Company and any Subsidiary shall not be deemed a
termination of employment, and (b) a Participant who is granted in writing a
leave of absence shall be deemed to have remained in the employ of the Company
during such leave of absence.

8.       Adjustments

         In the event of any change in the outstanding Common Stock by reason of
a stock split, spin-off, stock dividend, stock combination or reclassification,
recapitalization or merger, change of control, or other similar event or
corporate change, the Committee shall adjust appropriately the number of Shares
subject to the Plan and available for or covered by Option grants and exercise
prices related to outstanding Option grants and make such other revisions to
outstanding Option grants as it deems are equitably required.

9.       Merger, Consolidation, Exchange, Acquisition, Liquidation or
         Dissolution

         In its absolute discretion, and on such terms and conditions as it
deems appropriate, coincident with or after the grant of any Option, the
Committee may provide that such Option cannot be exercised after (i) the merger
or consolidation of either the Company, MedCath Intermediate Holdings, Inc., or
MedCath Incorporated into another corporation, (ii) the exchange of all or
substantially all of the assets of either the Company, MedCath Intermediate
Holdings, Inc., or MedCath Incorporated for the securities of another
corporation, (iii) the acquisition by another corporation of 80% or more of the
Company's, MedCath Intermediate Holdings, Inc.'s, or MedCath Incorporated's then
outstanding shares of voting stock, or (iv) the recapitalization,
reclassification, liquidation or dissolution of the Company, MedCath
Intermediate Holdings, Inc., or MedCath Incorporated, (a "Transaction"), and if
the Committee so provides that such

                                       6
<PAGE>   7

Option cannot be exercised, it shall, on such terms and conditions as it deems
appropriate, also provide, either by the terms of such Option or by a resolution
adopted prior to the occurrence of such Transaction, that, for some reasonable
period of time prior to such Transaction, such Option shall be exercisable as to
all shares subject thereto, notwithstanding anything to the contrary herein (but
subject to the provisions of Paragraph 6(b)) and that, upon the occurrence of
such Transaction, such Option shall terminate and be of no further force or
effect; provided, however, in lieu of so providing that an Option cannot be
exercised after a Transaction, the Committee may provide, in its absolute
discretion, that the Option shall remain exercisable after a Transaction in
accordance with its original terms, except upon exercise of such Option, the
holder thereof shall receive the kind and amount of securities and/or other
property, or the cash equivalent thereof, receivable as a result of such
Transaction by the holder of a number of shares of stock for which such Option
could have been exercised immediately prior to such Transaction.

10.      Amendment and Termination

         The Committee shall have the authority to make such amendments to any
terms and conditions applicable to outstanding Option grants as are consistent
with this Plan provided that, except for adjustments under Paragraph 8 or 9
hereof, no such action shall modify such Option grant in a manner adverse to the
Participant without the Participant's consent except as such modification is
provided for or contemplated in the terms of the Option grant.

         The Board of Directors may amend, suspend or terminate the Plan except
that no such action, other than an action under Paragraph 8 or 9 hereof, may be
taken which would, without shareholder approval, increase the aggregate number
of Shares subject to Options under the Plan, decrease the exercise price of
outstanding Options, change the requirements relating to the Committee or extend
the term of the Plan.

11.      Foreign Options and Rights

         The Committee may grant Options to Employees who are subject to the
laws of nations other than the United States, which Option grants may have terms
and conditions that differ from the terms thereof as provided elsewhere in the
Plan for the purpose of complying with foreign laws.

12.      Withholding Taxes

         The Company shall have the right to deduct from any cash payment made
under the Plan any federal, state or local income or other taxes required by law
to be withheld with respect to such payment. It shall be a condition to the
obligation of the Company to deliver shares upon the exercise of an Option that
the Participant pay to the Company such amount as may be requested by the
Company for the purpose of satisfying any liability for such withholding taxes.
Any Option Agreement may provide that the Participant may elect, in accordance
with any conditions set forth in such Option Agreement, to pay a portion or all
of such withholding taxes from the Participant's regular wages earned from the
Company or in shares of Common Stock.

                                       7
<PAGE>   8

13.      Effective Date and Termination Dates

         The Plan shall be effective on and as of the date of its approval by
the stockholders of the Company and shall terminate ten years later, subject to
earlier termination by the Board of Directors pursuant to Paragraph 10.

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]